

Evaluating Size-Specific Dose Estimate (SSDE) as an Estimate of Organ Doses from Routine CT Exams Derived from Monte Carlo Simulations

Anthony J. Hardy, PhD^{1*}; Maryam Bostani, PhD^{2,3}; Hyun J. Kim, PhD²; Chris Cagnon, PhD^{2,3}; Maria Zankl, MSc⁴; Michael McNitt-Gray, PhD^{2,3}

Running title: SSDE as estimates of Organ Doses

¹Livermore National Laboratory, Materials Engineering Division/Non-destructive Evaluation Group, Livermore, CA, 94550

²Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, Livermore, 90024

³Physics and Biology in Medicine Graduate Program, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, 90024

⁴Helmholtz Zentrum München, German Research Center for Environmental Health (GmbH), Institute of Radiation Medicine, Ingolstaedter Landstrasse 1, Neuherberg 85764, Germany

***Corresponding Author**
ajhardy06@gmail.com

1 **ABSTRACT**

2 **Purpose**

3 The size specific dose estimate (SSDE) is a metric that adjusts $CTDI_{vol}$ to account for patient size. While
4 not intended to be an estimate of organ dose, AAPM Report 204 notes the difference between the patient
5 organ dose and SSDE is expected to be 10-20%. The purpose of this work was therefore to evaluate
6 SSDE against estimates of organ dose obtained using Monte Carlo (MC) simulation techniques applied to
7 routine exams across a wide range of patient sizes.

8
9 **Materials and Methods**

10 SSDE was evaluated with respect to organ dose based on representative organs for each of three routine
11 protocols: (1) brain parenchyma dose in routine head exams; (2) lung and breast dose in routine chest
12 exams; and (3) liver, kidney, and spleen dose in routine abdomen/pelvis exams. For each exam, voxelized
13 phantom models were created from existing models or derived from clinical patient scans. For routine
14 head exams, 15 patient models were used which consisted of 10 GSF/ICRP voxelized phantom models
15 and 5 pediatric voxelized patient models created from CT image data. For the routine chest exams, data
16 from 161 patients were collected with a D_w range of ~16 to 44 cm. For the routine abdomen/pelvis exams,
17 data from 107 patients were collected with a range of D_w from ~16 to 44 cm. Image data from these
18 patients were segmented to generate voxelized patient models. For routine head exams, fixed tube current
19 (FTC) was used while tube current modulation (TCM) data for body exams were extracted from raw
20 projection data. The voxelized patient models and tube current information were used in detailed MC
21 simulations for organ dose estimation. For all exams, the size metric used was water equivalent diameter
22 (D_w). Organ doses from MC simulation were normalized by $CTDI_{vol}$ and parameterized as a function of
23 D_w . For each patient scan, the SSDE was obtained using D_w and $CTDI_{vol}$ values of each scan, according to
24 AAPM Report 204 for body scans and Report 293 for head scans. For each protocol and each patient,
25 normalized organ doses were compared to SSDE. A one-sided tolerance limit covering 95% ($p = 0.95$) of

26 the population with 95% confidence ($\alpha = 0.05$) was used to assess the upper tolerance limit (T_U) between
27 SSDE and normalized organ dose.

28

29 **Results**

30 For head exams, the T_U between SSDE and brain parenchyma dose was observed to be 12.5%. For routine
31 chest exams, the T_U between SSDE and lung and breast dose was observed to be 35.6% and 68.3%,
32 respectively. For routine abdomen/pelvis exams, the T_U between SSDE and liver, spleen, and kidney dose
33 was observed to be 30.7%, 33.2%, and 33.0%, respectively.

34

35 **Conclusions**

36 The T_U of 20% between SSDE and organ dose was found to be insufficient to cover 95% of the sampled
37 population with 95% confidence for all of the organs and protocols investigated, except for brain
38 parenchyma dose. For the routine body exams, excluding the breasts, a wider threshold difference of ~30-
39 36% would be needed for the coverage and confidence investigated in this study.

40

41 **Keywords:** Size-specific dose estimate, Monte Carlo dose simulations, TCM, routine CT exams

42 1. INTRODUCTION

43 CT is widely used as a diagnostic tool due to its ability to acquire cross-sectional images of
44 patient anatomy in a relatively short amount of time. In 2006, abdominal/pelvic, head, and chest CT scans
45 conducted within the United States accounted for 32%, 28%, and 16%, respectively, of all CT procedures
46 [1]. Additionally, the 2015 UC DOSE study found that, across twelve University of California medical
47 centers, abdominal/pelvic, chest, and head scans accounted for 32%, 16%, and 13% of all adult CT
48 procedures [2]. Routine examinations may be reasonably assumed to comprise the large majority of these
49 CT procedures. Thus, patient organ dose assessments from routine procedures are of substantial interest.

50 The volumetric Computed Tomography Dose Index ($CTDI_{vol}$) and dose-length product (DLP),
51 two commonly-reported CT dose metrics, are understood to not necessarily be indicative of patient
52 dosimetry [3]. This is primarily due to the differences in composition and geometry of the CTDI phantom
53 relative to a human patient. There are at present two ways of estimating patient organ dose from CT: (1)
54 in vitro empirical dose measurements using dosimeters such TLDs or MOSFETs within anthropomorphic
55 phantoms or cadavers and (2) dose calculations from MC software packages.

56 Both of these approaches have inherent advantages and disadvantages in the current context of
57 modern CT dosimetry. In brief, in vitro empirical measurements are advantageous in that dose estimates
58 come directly from the CT source, meaning that specific automatic exposure control (AEC) strategies of
59 manufacturers are captured in these dose readings, provided that the dosimeters are properly calibrated.
60 In addition, this method does allow for repeated exposures. A drawback to physical measurements,
61 however, is that oftentimes even the most sophisticated anthropomorphic phantoms models, such as the
62 CIRS phantoms [4] and even cadavers [5], may not have the breadth to be reflective of the range of actual
63 patient anatomy experienced clinically. In vivo measurements can be done, such as in the study where
64 TLDs were placed in the colon and used for CT colonography dosimetry [6]. However, in vivo
65 measurements are often invasive. Moreover, the dose distribution within the patient is not necessarily
66 uniform, particularly near the surface of a patient [7]. Therefore, adequate spatial sampling of the non-
67 uniform distribution to obtain an estimate of organ dose may require a large number of dosimeters.

68 MC approaches address some of the shortcomings of the in vitro, empirical methods. MC
69 methods obviate the need for dosimeters entirely due to the mathematical transportation of particles
70 through a particular medium. Moreover, the availability of highly-sophisticated, deformable,
71 mathematical phantoms models, such the XCAT family models [8], allows for permutations of human
72 anatomy. Commercially-available dose management software packages, used widely in hospitals and
73 medical centers, often employ MC simulations based on these sophisticated, mathematical models of
74 human anatomy. However, this approach comes with its own set of challenges. As with any MC
75 simulation, the accuracy of the MC approach is highly dependent upon the accuracy of the simulation set
76 up [9], [10]. For CT dosimetry, this accuracy requires both sufficient scanner x-ray source descriptions
77 and accurate representations of both vendor-specific AEC algorithms and patient anatomic
78 representations. Furthermore, MC methods require extensive validation, usually with equivalent empirical
79 measurements, and can be time prohibitive and computationally expensive.

80 While not originally intended to be a measure of organ dose, SSDE does have the potential to
81 provide an accessible and quick estimate of organ dose in lieu of empirical measurement and MC
82 approaches. Per Report 204, SSDE was based on fixed tube current (FTC) [11], [12]. A study conducted
83 by Moore et al. investigated the correlation between absolute organ dose from TCM scans with SSDE in
84 pediatric and adult patients using in vitro organ dose measurements from four CIRS anthropomorphic
85 phantoms [13]. This study used effective diameter (*ED*) as the metric of patient and phantom size and
86 compared patient organ dose derived from SSDE-to-organ dose conversion coefficients to published MC
87 results of computational phantoms. The Moore et al. study found that the average correlation of SSDE
88 and absolute organ dose was found to be within $\pm 10\%$ of unity [13]. Another study conducted by Sinclair
89 et al. compared correlations of $CTDI_{vol}$ -normalized organ dose versus *ED* against SSDE for
90 chest/abdomen/pelvis exams [14]. In this study, the organ dose values were from in vitro measurements
91 of 8 cadavers representing a range of sizes from the University of Florida. In this study, the difference
92 between the average overall organ dose measurements from the cadavers and SSDE ranged from -23% to
93 4% [14]. In both these studies, *ED* was used as the metric of patient size, whereas the attenuation-based

94 size metric water equivalent diameter (D_w) is now more commonly used [15]. Moreover, the Moore et al.
95 study indirectly compared SSDE to empirical measurements and MC simulations of hybrid computational
96 phantom models from Lee et al. and Li et al. [16], [17]. As mentioned above, the use of in vitro
97 measurements from detailed physical phantoms and MC simulations of the highly-sophisticated
98 computational phantom may not be representative of variation of patient habitus.

99 Therefore, the purpose of this study was to evaluate SSDE as an estimate of organ doses derived
100 from the MC simulation of routine exams. In contrast to the previous studies, this evaluation of SSDE
101 was performed on a direct, per-organ basis across a wide range of patient habitus for routine head, chest,
102 and abdomen/pelvis exams. Specifically, this study evaluated the SSDE in relation to brain parenchyma
103 dose from routine head exams; lung and breast dose from routine chest exams; and liver, spleen, and
104 kidney dose from routine abdomen/pelvis exams.

105

106 **2. MATERIALS AND METHODS**

107 **2.A Voxelized patient cohorts**

108 *2.A.1 Routine Head Exams*

109 The patient data for the routine head exams was from Hardy et al [18]. This data consists of a
110 total of 15 voxelized patient models. Ten voxelized phantom models from the GSF (Helmholtz Zentrum
111 München, German Research Center for Environment Health, Institute of Radiation Protection,
112 Neuherberg, Germany) family [19] and the ICRP (International Commission Radiological Protection)
113 voxelized reference male and female [20], [21] were used. These models had all radiosensitive organs
114 identified. The eight GSF voxel-based models were generated from CT images with up to 131 organs and
115 anatomic structures segmented. Two of the voxelized models were the ICRP reference male and female
116 models. They were each based on modifications of two corresponding male and female GSF models of
117 similar external dimensions. The GSF/ICRP voxelized models used in this study had the in-plane
118 resolution subsampled from the original by approximately a factor of four or eight to decrease
119 computation time [19]–[21]. The remaining five patient models were derived from pediatric patient data

120 in order to extend the pediatric size range. These data sets were collected from clinically-indicated scans
121 under IRB approval.

122 The routine head protocols were performed with FTC. The details of the protocol are listed in
123 **Table 1**. Because the analyses will be performed on a per mAs basis, the $CTDI_{vol,16}/mAs$ value is
124 reported.

125 **Table 1:** Routine helical head scanning protocol and associated $CTDI_{vol,16}$ per mAs for the scan from
126 Hardy et al [18]

Parameter	Setting
kV	120
Rotation time (s)	0.5
Helical pitch	0.55
Nominal collimation (mm)	28.8
Bowtie filter	Standard
$CTDI_{vol,16}/mAs$ (mGy/mAs)	0.24

127
128 *2.A.2 Routine Chest Exams Patient Cohort*
129 To estimate lung and glandular breast tissue dose from routine chest exams, data were collected
130 under IRB approval from 161 patients undergoing clinically indicated CT exams (19 pediatric females, 23
131 pediatric males, 53 adult females, 65 adult males) with a range of D_w values from 16 to 44 cm. The
132 routine chest examinations were performed using tube current modulation (TCM). Data were collected
133 from four different scanners: Sensation 16 (S16), Sensation 64 (S64), Definition AS64, and SOMATOM
134 Force (all from Siemens Healthineers, Forchheim, Germany). **Table 2** summarizes the scanning protocols
135 for the routine chest protocols used for the four scanners. Because of the presence of pediatric and
136 bariatric patients, some alterations of the routine chest protocol—such as reduced tube voltage for
137 pediatric patients, reduced pitch for bariatric patients ($D_w \approx 40$ or greater), and different bowtie filters for
138 pediatric patients—were present in this cohort. All scans were performed with TCM (CAREdose4D,
139 Siemens Healthineers, Germany) with the CAREdose4D Quality Reference mAs (QRM) value as
140 described in **Table 2** and strength set to “Average.” For all cases, the TCM data was extracted from the

141 raw projection data that was collected at the time of the scan. The chest scans were all performed in the
 142 supine position. Image data were reconstructed at 500 mm field-of-view (FOV) in order to ensure patient
 143 anatomy is contained within the FOV. For bariatric patients, portions of peripheral anatomy were often
 144 still outside of the 500 mm FOV. In these cases, an extended FOV (eFOV) of 650 mm was employed to
 145 encompass the anatomy for larger patients. **Table 3** summarizes the quantity of patient data from each
 146 scanner.

147

148 **Table 2:** Routine chest scanning parameters for the four scanners used in this investigation

Parameter	S16	S64	AS64	Force
kV*	100	120	120	120
Quality reference mAs (QRM)	140	140	140	140
Rotation time (s)	0.5	0.5	0.5	0.5
Pitch [†]	1.0	1.0	1.0	1.0
Nominal collimation (mm)	24.0	19.2	19.2	57.6
Bowtie filter [‡]	Body	Body	Body/W1	Body/W1

149 * Most of the pediatric patients were scanned with 100 kV.

150 [†]Bariatric patients were scanned with pitches lower than 1.0

151 [‡]For the AS64 and Force scanners, the pediatric patients were scanned with Head/W2 bowtie filter


152

153 **Table3:** Overview of chest scans collected from the different scanners used in this study

Patient cohort	S16	S64	AS64	Force	Total
Adult males	-	42	12	11	65
Adult females	-	29	12	12	53
Pediatric males	6	12	5	1	24
Pediatric females	7	5	7	0	19
Total	13	88	36	24	161

154

155 To use the patient image data for MC simulations, patient anatomy contained within the image
 156 data were voxelized. Voxels within the image data were modeled as either lung, fat, water, muscle, bone
 157 or air then subdivided into one of seventeen density levels in relation to their CT number [22], [23]. The
 158 lung tissue was semi-automatically contoured in both female and male patients; glandular breast tissue,
 159 however, was only segmented for female patients [24]. **Figure 1** contains examples of segmented male
 160 and female patient image data and resulting voxelized models.



162

163 **Figure 1:** A) Segmented images of a male patient who underwent clinically-indicated chest CT exam
 164 with B) the voxelization of the segmented image data for use in MC simulations. In A), only the lung
 165 tissue (red outline) is segmented. C) Segmented images of a female patient who underwent clinically-
 166 indicated chest CT exam with D) the voxelization of the segmented image data for use in MC simulations.
 167 In C), both lung (red outline) and glandular breast tissue (yellow outline) are segmented.
 168

169 2.A.3 Routine Abdominal/Pelvic Exams

170 To estimate liver, spleen, and kidney dose from routine abdomen/pelvis exams, data were
 171 collected under IRB approval from 107 patients undergoing clinically indicated CT exams (9 pediatric
 172 females, 12 pediatric males, 44 adult females, 42 adult males) with a range of D_w values from 16 to 44
 173 cm. The routine abdomen/pelvis examinations were performed using TCM. Data were collected from
 174 three different scanners: Sensation 64 (S64), Definition AS64, and SOMATOM Force (all from Siemens
 175 Healthineers, Forchheim, Germany). As with the routine chest protocol in Sec. 2.A.2, some alterations of
 176 the routine abdomen/pelvis protocol were present in this cohort because of the presence of pediatric and
 177 bariatric patients (again, defined as $D_w \approx 40$ or greater). All scans were performed with TCM
 178 (CAREdose4D, Siemens Healthineers, Germany) with the QRM value as described in **Table 4** and

179 strength set to “Average.” For call cases, the TCM data was extracted from the raw projection data that
 180 was collected at the time of the scan. **Table 4** contains the remaining scanning parameter for the
 181 abdomen/pelvis protocols for the three scanners of this investigation. All of the abdomen/pelvis scans
 182 were performed in the supine position, and the image data were reconstructed at 500 mm field-of-view
 183 (FOV) in order to ensure patient anatomy is contained within the FOV. An extended FOV (eFOV) of 650
 184 mm was utilized to encompass the anatomy for bariatric patients. **Table 5** summarizes the quantity of
 185 patient data from each scanner. The abdominal/pelvic image data were voxelized for utilization in MC
 186 simulations in the same manner as Sec 2.A.2 above. **Figure 2** contains examples of segmented female
 187 patient image data and resulting voxelized models.

188

189 **Table 4:** Routine abdominal/pelvis scanning parameters for the three scanners used in this investigation

Parameter	S64	AS64	Force
kV [*]	120	120	120
Quality reference mAs (QRM)	180	180	180
Rotation time (s)	0.5	0.5	0.5
Pitch [†]	1.0	1.0	1.0
Nominal collimation (mm)	19.2	19.2	57.6
Bowtie filter [‡]	Body	Body/W1	Body/W1

190

* Most of the pediatric patients were scanned with 100 kVp.

191

†Bariatric patients were scanned with pitches lower than 1.0

192

‡For the AS64 and Force scanners, the pediatric patients were scanned with Head/W2 bowtie filter


193

194 **Table 5:** An overview of abdomen/pelvis scans collected from the different scanners used in this study

Patient cohort	S64	AS64	Force	Total
Adult males	30	8	4	42
Adult females	32	7	5	44
Pediatric males	11	-	1	12
Pediatric females	9	-	0	9
Total	82	15	10	107

195

196



197
 198 **Figure 2:** A) Segmented images of a female patient who underwent clinically-indicated abdomen/pelvis
 199 CT exam with B) the voxelization of the segmented image data for use in MC simulations.
 200

201 **2.B. Patient size metrics**

202 Water equivalent diameter (D_w) was chosen as the metric of patient for this investigation. AAPM
 203 Report 220 describes two methods of estimating D_w : one based on values extracted from the topogram
 204 and one based on CT image data [15]. For this study, both approaches were used, depending on the data
 205 available. For those patients whose data was collected on either the Sensation 16 or the Sensation 64
 206 scanners, estimates of D_w were based on the CT numbers in the image data. This was done because the
 207 CT scan radiographs (i.e. topograms) for these patients were not available. Specifically, D_w was
 208 estimated at the center of the image series using the methods outlined in AAPM Report 220 for assessing
 209 D_w from CT numbers in image data [25]. For the patients whose data was gathered from the Definition
 210 AS64 or the Force scanners, estimates of D_w were extracted from the topogram. For each patient model,
 211 D_w was assessed at the longitudinal center of the image series while the estimates of D_w were obtained
 212 from the topogram at that center location. This method of acquiring D_w from the topogram is also based
 213 on the methodology outline in AAPM Report 220 wherein D_w is calculated using the lateral (LAT) and
 214 anterior-posterior (AP) measurements also found within the topogram [25].

215

216 **2.C. MC simulations**

217 The MC simulation package used for this study was MCNPX. Modifications to MCNPX allowed
218 for the implementation of “equivalent source” and “equivalent bowtie” of the four MDCT scanners used
219 in this investigation [26]. All simulations were performed in photon transport mode with a 1 keV low-
220 energy cut-off. All simulations were performed with 10^7 particle histories to ensure a statistical
221 uncertainty of less than 1%. In order to incorporate the TCM data into the MC simulation, the methods
222 described by Angel et al. were used in that an additional text file containing the TCM information was
223 generated by extracting the tube current information from the raw projection data [24]. In the text file, the
224 tube current $I(z, \theta)$ was expressed as a function of table position (z) and tube angle (θ). MCNPX
225 simulations were performed using the computational and storage services associated with the Hoffman2
226 Shared Cluster provided by UCLA Institute for Digital Research and Education’s Research Technology
227 Group.

228

229 **2.D Dose Analysis**

230 Absolute organ dose values were estimated from MC simulations by applying scanner-, tube
231 voltage-, collimation-specific normalization factors [27]. $CTDI_{vol}$ -normalized organ dose values (nD_{organ})
232 from the routine exams investigated were calculated by normalizing the absolute organ doses by $CTDI_{vol}$
233 values. $CTDI_{vol}$ -normalized brain parenchyma dose values (nD_{brain}) from routine head exams were
234 calculated using $CTDI_{vol,16}$. $CTDI_{vol}$ -normalized lung and breast dose values (nD_{lung} and nD_{breast}) were
235 calculated using $CTDI_{vol,32}$ for normalization. Similarly, $CTDI_{vol,32}$ was used to normalize liver, kidney,
236 and spleen dose values (nD_{liver} , nD_{kidney} , and nD_{spleen} , respectively). All $CTDI_{vol}$ values were taken from the
237 patient protocol page produced by the scanners utilized in this investigation. Lastly, each nD_{organ} was
238 parameterized as an exponential function with respect to D_w using the same form as AAPM Report 204.
239 Regression analyses were used to determine the coefficients of the exponential function for each scan
240 protocol and organ.

241

242 **2.E Statistical Analysis**

243 nD_{organ} values from the routine exams were compared to SSDE f -factors (henceforth referred to as
 244 SSDE). This study used the SSDE from AAPM Report 293 for head exams and AAPM 204 for body
 245 exams as the basis of comparison [11], [12]. For an individual patient, $\Delta D_{SSDE,organ}$ is the nD_{organ} value
 246 relative to the SSDE value based on the patient's D_w estimate. This was calculated for each patient, for
 247 each protocol, and for each organ. The definition of $\Delta D_{SSDE,organ}$ for a given patient i is given by **Eq. 1**:

$$248 \quad (\Delta D_{SSDE,organ})_i (\%) = \frac{(nD_{organ})_i - SSDE(D_w)_i}{SSDE(D_w)_i} \times 100\% \quad \text{Eq. 1}$$

249
 250
 251 For each organ dose from each protocol, the average difference relative to SSDE ($\overline{\Delta D_{SSDE,organ}}$),
 252 and the standard deviation of the difference relative to SSDE ($\Delta S_{SSDE,organ}$) were calculated using **Eq. 2**
 253 and **Eq. 3**, respectively.

$$254 \quad \overline{\Delta D_{SSDE,organ}} (\%) = \frac{1}{N} \sum_{i=1}^N |(\Delta D_{SSDE,organ})_i| \quad \text{Eq. 2}$$

$$255 \quad \Delta S_{SSDE,organ} (\%) = \sqrt{\frac{1}{N-1} \sum_{i=1}^N (|(\Delta D_{SSDE,organ})_i| - \overline{\Delta D_{SSDE,organ}})^2} \quad \text{Eq. 3}$$

256 Where N is the total number of patients.

257 A second analysis was performed to assess the number of cases where the estimated organ doses
 258 agreed with SSDE values to within a certain tolerance (either $\pm 20\%$ and $\pm 30\%$ of the SSDE). In the plots
 259 found in Sec. 3 below, this is graphically illustrated by using shaded regions that correspond to $\pm 20\%$ and
 260 $\pm 30\%$ of the SSDE. The proportion of the data points within these regions (C_p) were given for each organ
 261 and was calculated using **Eq. 4**.

$$262 \quad C_p = \frac{\# \text{ of points within the regions relative to SSDE}}{N} \quad \text{Eq. 4}$$

263 Lastly, in order to determine the coverage of SSDE as an estimate of organ dose over a fixed proportion
 264 of the population, a one-sided, upper tolerance limit was calculated. The one-sided tolerance limit was

265 utilized because this study is concerned with assessing the upper tolerance limit (T_U) of the difference
266 between normalized organ dose and the SSDE values. The coverage factor (proportion of the population
267 of nD_{organ} values, p) used to construct the tolerance limit was 95% ($p = 0.95$) with a confidence level of
268 95% ($\alpha = 0.05$). Using the upper bound of 20% difference between SSDE and patient dose mentioned in
269 AAPM Report 204 as a point of comparison, the hypotheses for this study were as follows:


270 1) Null hypothesis (H_0): $T_U \leq 20\%$ with a confidence of 95% ($\alpha = 0.05$) covering 95% of the
271 population ($p = 0.95$).

272 2) Alternative hypothesis (H_I): $T_U > 20\%$ with a confidence of 95% ($\alpha = 0.05$) covering 95% of the
273 population ($p = 0.95$).

274 Where T_U is calculated as

$$275 \quad T_U = \overline{\Delta D_{SSDE,organ}} + k_1(\alpha, p, N) \Delta S_{SSDE,organ} \quad \text{Eq. 5}$$

276 Where k_I is the factor that determines the upper limit to cover proportion p with confidence $(1-\alpha)\%$
277 using sample size N [28]. The upper tolerance limit of 30% difference between SSDE and patient dose
278 can be derived analogously. **Figure 3** is the process workflow for evaluating SSDE against organ dose.



280

281 **Figure 3:** The workflow process for this study in the instances where raw projection data was needed.
 282 Starting with (I) raw projection data as input, (II) image data were reconstructed and segmented. (III)
 283 Tube current profiles was extracted from the raw data. (IV) The segmented image data was voxelized by
 284 mapping CT number to a material designation using a look-up table. The TCM data (III) and the
 285 voxelized patient model (IV) were incorporated into MCNPX to get (V) absolute organ doses. Absolute
 286 organ doses (V) were normalized by (VI) $CTDI_{vol}$ from the patient protocol page to yield (VII) $CTDI_{vol}$ -
 287 normalized organ doses. (VIII) From the topogram, estimates of D_w (IX) were then extracted. In this
 288 workflow, D_w estimates can also be taken from the image data. The D_w estimates were used to calculate
 289 the SSDE (X) from AAPM Reports 204 and 220. Lastly SSDE was then evaluated (XI) relative to MC-
 290 derived $CTDI_{vol}$ -normalized organ doses. Where raw projection data was not needed, such as for the
 291 routine head scans, I and III were skipped and $CTDI_{vol,16}/mAs$ measurement was used in lieu of VI.
 292

293 3. RESULTS

294 3.A SSDE relative to brain parenchyma dose from routine head exams


295 **Table 6** below contains the D_w estimates, SSDE from AAPM Report 293, nD_{brain} values, and
 296 difference (%) of nD_{brain} values relative to the SSDE ($\Delta D_{SSDE,brain}$). In addition, the mean ($\overline{\Delta D_{SSDE,brain}}$)
 297 and standard deviation of brain dose relative to SSDE ($\Delta S_{SSDE,brain}$) are also included in **Table 6**. The
 298 patient population did include both pediatric and adult patients with a range of D_w from ~11 to 20 cm.
 299 $\Delta D_{SSDE,brain}$ values ranged from -5.9% to 13.8%. $\overline{\Delta D_{SSDE,brain}}$ was observed to be 4.4% and $\Delta S_{SSDE,brain}$ was
 300 observed to be 3.2%. All 15 nD_{brain} values were within 20% of SSDE ($C_p = 100.0\%$). Using $N = 15$, T_U
 301 for SSDE covering 95% of the population for nD_{brain} with 95% confidence was observed to be 12.5%.

302 **Figure 4** shows below nD_{brain} parameterized as an exponential function with D_w in relation to SSDE
 303 values from AAPM Report 293.

304
 305 **Table 6:** D_w estimates, SSDE, nD_{brain} values, and difference of nD_{brain} values relative to the SSDE
 306 ($\Delta D_{SSDE,brain}$) for the patients investigated

Name	D_w (cm)	SSDE	nD_{brain}	$\Delta D_{SSDE,brain}$ (%)
Peds2	12.6	1.07	1.12	-4.8
Peds1	10.6	1.19	1.17	1.4
Baby	11.1	1.16	1.16	-0.7
Peds3	15.6	0.93	0.98	-5.3
Peds5	17.1	0.86	0.81	5.5
Peds4	15.7	0.92	0.89	3.5
Child	17.2	0.86	0.91	-6.2
Helga	18.2	0.82	0.81	0.4
Irene	17.1	0.86	0.84	2.4
Golem	18.3	0.81	0.86	5.5
Visible Human	19.6	0.76	0.74	2.3
Regina	19.9	0.75	0.85	-13.8
Donna	18.7	0.79	0.83	5.0
Rex	20.2	0.74	0.78	5.4
Frank	19.2	0.78	0.73	5.9
$\overline{\Delta D_{SSDE,brain}}$				4.4
$\Delta S_{SSDE,brain}$				3.2
T_U				12.5

307
 308



309
 310 **Figure 4:** nD_{brain} values in relation to SSDE from AAPM Report 293 with shaded areas corresponding to
 311 $\pm 20\%$ and $\pm 30\%$ of the SSDE


312

313 3.B SSDE relative to lung and breast dose from routine chest exams

314 **Figure 5A** contains nD_{lung} parameterized as an exponential function with D_w in relation to SSDE
 315 from AAPM Report 204. For nD_{lung} , $\Delta D_{SSDE, lung}$ values ranged from -60.4% to 20.1%. $\overline{\Delta D_{SSDE, lung}}$ was
 316 observed to be 15.3% and $\Delta S_{SSDE, lung}$ was observed to be 10.9%. Of the 160 cases, 119 of the nD_{lung} values
 317 were within 20% of SSDE ($C_p = 74.4\%$) while 148 of the nD_{lung} values were within 30% of SSDE ($C_p =$
 318 92.5%). Only 12 of the nD_{lung} cases were beyond 30% of SSDE ($C_p = 7.5\%$). Using $N = 160$, T_U for SSDE
 319 covering 95% of the population for nD_{lung} with 95% confidence was observed to be 35.6%.

320 **Figure 5B** shows nD_{breast} parameterized as an exponential function with D_w in relation to SSDE.
 321 For nD_{breast} , $\Delta D_{SSDE, breast}$ values ranged from -90.8% to 10.4%. $\overline{\Delta D_{SSDE, breast}}$ was observed to be 31.8% and
 322 $\Delta S_{SSDE, breast}$ was observed to be 18.7%. Of the 85 cases, 26 of the nD_{breast} values were within 20% of SSDE
 323 ($C_p = 30.6\%$) while 44 of the nD_{breast} values were within 30% of SSDE ($C_p = 51.8\%$). 41 of the nD_{breast}
 324 cases were beyond 30% of SSDE ($C_p = 48.2\%$). Using $N = 85$, T_U for SSDE covering 95% of the
 325 population for nD_{breast} with 95% confidence was observed to be 60.7%. **Table 7** contains the summary
 326 statistics for nD_{lung} and nD_{breast} values relative to the SSDE and the T_U for each organ. **Table 10** contains
 327 the frequency table for nD_{lung} and nD_{breast} values relative to 20% and 30% of the SSDE.

328



329

330 **Figure 5: A)** nD_{lung} and **B)** nD_{breast} values in relation to SSDE from AAPM Report 204 with shaded areas
 331 corresponding to $\pm 20\%$ and $\pm 30\%$ of the SSDE

332 **Table 7:** Summary statistics for nD_{lung} and nD_{breast} values relative to SSDE and the T_U for each estimate of
 333 normalized lung dose

	nD_{lung}	nD_{breast}
$\overline{\Delta D_{SSDE,organ}}$ range (%)	-60.4 to 20.1	-90.8 to 10.4
$\overline{\Delta D_{SSDE,organ}}$ (%)	15.3	31.8
$\Delta S_{SSDE,organ}$ (%)	10.9	18.7
T_U (%)	35.6	68.3

334

335 **Table 8:** Frequency table of nD_{lung} and nD_{breast} relative to SSDE from routine TCM chest exams

	nD_{lung} (N=160)	nD_{breast} (N=85)
within $\pm 20\%$ of SSDE	119 $C_p = 74.4\%$	26 $C_p = 30.6\%$
within $\pm 30\%$ of SSDE	148 $C_p = 92.5\%$	44 $C_p = 51.8\%$
beyond $\pm 30\%$ of SSDE	12 $C_p = 7.5\%$	41 $C_p = 48.2\%$


336

337 *3.C SSDE relative to liver, spleen, and kidney dose from routine abdominal/pelvis exams*

338 **Figure 6A** contains nD_{liver} parameterized as an exponential function with D_w in relation to SSDE
 339 from AAPM Report 204. $\Delta D_{SSDE,liver}$ values ranged from -54.0% to 28.7%. $\overline{\Delta D_{SSDE,liver}}$ was observed to be
 340 13.1% and $\Delta S_{SSDE,liver}$ was observed to be 9.2%. Of the 107 cases, 88 of the nD_{liver} values were within 20%
 341 of SSDE ($C_p = 82.2\%$) while 104 of the nD_{liver} values were within 30% of the SSDE ($C_p = 97.2\%$). Only 3
 342 of the nD_{liver} cases were beyond 30% of SSDE ($C_p = 2.8\%$). Using $N = 107$, T_U for SSDE covering 95%
 343 of the population for nD_{liver} with 95% confidence was observed to be 30.7%.

344 **Figure 6B** contains nD_{spleen} parameterized as an exponential function with D_w in relation to SSDE
 345 from AAPM Report 204. $\Delta D_{SSDE,spleen}$ values ranged from -44.4% to 35.4%. $\overline{\Delta D_{SSDE,spleen}}$ was observed to
 346 be 14.1% and $\Delta S_{SSDE,spleen}$ was observed to be 10.0%. Of the 107 cases, 81 of the nD_{spleen} values were
 347 within 20% of SSDE ($C_p = 75.7\%$) while 99 of the nD_{spleen} values were within 30% of SSDE ($C_p =$
 348 92.5%). Only 8 of the nD_{spleen} cases were beyond 30% of SSDE ($C_p = 7.5\%$). T_U for SSDE covering 95%
 349 of the population for nD_{spleen} with 95% confidence was observed to be 33.2%.

350 **Figure 6C** contains nD_{kidney} parameterized as an exponential function with D_w in relation to SSDE
351 from AAPM Report 204. $\Delta D_{SSDE,kidney}$ values ranged from -49.6% to 47.3%. $\overline{\Delta D_{SSDE,kidney}}$ was observed to
352 be 13.7% and $\Delta S_{SSDE,kidney}$ was observed to be 10.1%. Of the 107 cases, 83 of the nD_{kidney} values were
353 within 20% of SSDE ($C_p = 77.6\%$) while 100 of the nD_{kidney} values were within 30% of the SSDE ($C_p =$
354 93.5%). Only 7 of the nD_{kidney} cases were beyond 30% of SSDE ($C_p = 6.5\%$). T_U for the SSDE covering
355 95% of the population for nD_{kidney} with 95% confidence was observed to be 33.0%. **Table 9** contains the
356 summary statistics for nD_{liver} , nD_{spleen} , and nD_{kidney} values relative to the SSDE and the T_U for each organ.
357 **Table 10** contains the frequency table for nD_{liver} , nD_{spleen} , and nD_{kidney} values relative to 20% and 30% of
358 SSDE.
359



360 **Figure 6:** A) nD_{liver} , B) nD_{spleen} , and C) nD_{kidney} values in relation to SSDE from AAPM Report 204 with
361 shaded areas corresponding to $\pm 20\%$ and $\pm 30\%$ of the SSDE
362

363

364 **Table 9:** Summary statistics for nD_{liver} , nD_{spleen} , and nD_{kidney} values relative to SSDE and the T_U for each
 365 organ for TCM abdomen/pelvis exams

	nD_{liver}	nD_{spleen}	nD_{kidney}
$\Delta D_{SSDE,organ}$ range (%)	-54.0 to 28.7	-44.4 to 35.4	-49.6 to 47.3
$\overline{\Delta D_{SSDE,organ}}$ (%)	13.1	14.1	13.7
$\Delta S_{SSDE,organ}$ (%)	9.2	10.0	10.1
T_U (%)	30.7	33.2	33.0

366

367 **Table 10:** Frequency table of nD_{liver} , nD_{spleen} , and nD_{kidney} relative to SSDE from routine TCM
 368 abdominal/pelvis exams

	nD_{liver} (N=107)	nD_{spleen} (N=107)	nD_{kidney} (N=107)
within $\pm 20\%$ of SSDE	88 $C_p = 82.2\%$	81 $C_p = 75.7\%$	83 $C_p = 77.6\%$
within $\pm 30\%$ of SSDE	104 $C_p = 97.2\%$	99 $C_p = 92.5\%$	100 $C_p = 93.5\%$
beyond $\pm 30\%$ of SSDE	3 $C_p = 2.8\%$	8 $C_p = 7.5\%$	7 $C_p = 6.5\%$

369

370 4. DISCUSSION


371 In this study, SSDE was compared to organ dose estimates from validated, direct MC simulation
 372 methods for three routine CT examinations across a wide range of patient sizes that included pediatric
 373 patients, adult patients, and, for the body scans, bariatric patients. The framework for evaluation,
 374 specifically for those exams using TCM, is outlined in **Figure 3**. The routine examinations included head
 375 exams performed with FTC, chest and abdomen/pelvis exams performed with TCM. Unlike the Moore et
 376 al. and Sinclair et al. studies mentioned previously, this study used D_w estimates taken either from patient
 377 topograms or image data to calculate the SSDE as opposed to the geometric size descriptor of ED .
 378 Moreover, this study directly evaluated SSDE on a per-organ basis with the aim of providing an upper
 379 tolerance limit for which SSDE will cover 95% of the population ($p = 0.95$) with 95% confidence ($\alpha =$
 380 0.05) for a particular organ. Lastly, the evaluation of the SSDE was performed to test if the $T_U \leq 20\%$
 381 between SSDE and patient dose as noted in AAPM Report 204.

382 For routine FTC head exams, this study observed that the T_U for the difference between nD_{brain}
383 and SSDE from AAPM 293 needed to cover 95% of the population with 95% confidence was 12.5%.
384 Additionally, as can be seen in **Figure 4**, all 15 nD_{brain} values were within 20% of SSDE ($C_p = 100.0\%$).
385 This suggests that the T_U of 20% between SSDE and patient dose noted in AAPM Report 204 may be
386 appropriate for routine head CT examinations employing FTC and that SSDE may serve as a good
387 estimate for brain parenchyma dose to within 12.5% for at least 95% of the population. There are two
388 explanations for this observation. The first is that SSDE reported in both AAPM Reports 293 and 204
389 were derived from FTC measurements and simulations [11], [12]. The second explanation is related to the
390 fact that, as noted in Hardy et al. [18], the head is composed of homogenous tissue encased in bone,
391 which SSDE in AAPM Report 293 took into consideration. Thus, as can be seen again in **Figure 4**, the
392 nD_{brain} as a function of D_w follows the SSDE curve, the average difference between them being less than
393 5% ($\overline{\Delta D_{SSDE,brain}} = 4.4\%$) with $\Delta S_{SSDE,brain}$ of only 3.2%. AAPM Report 293 does not explicitly note the
394 same $\pm 20\%$ difference between SSDE and patient dose (brain parenchyma dose in this case) as in AAPM
395 Report 204 [11], [12]. AAPM Report 293, however, is an extension of AAPM Report 204 [11], [12].

396 For routine chest, this study evaluated SSDE against both $CTDI_{vol,32}$ -normalized lung and breast
397 doses. This study observed that, when using $CTDI_{vol,32}$ as the normalization for lung dose, the T_U for the
398 difference between nD_{lung} and SSDE needed to cover 95% of the population with 95% confidence was
399 35.6%. This result suggests that the 20% difference between SSDE and patient dose noted in AAPM
400 Report 204 might not be sufficient for SSDE to cover 95% of nD_{lung} cases from routine chest exams
401 employing TCM. Rather, the results of this study suggest that a wider tolerance may be needed in order
402 for SSDE to serve as an estimate of lung dose. One possible reason for this has to do with the longitudinal
403 modulation provided by CAREdose4D. In terms of dose reduction, TCM has been shown to reduce lung
404 and breast dose relative to FTC in chest exams [29]. Because of the lower overall normalized dose
405 provided by TCM relative to FTC, SSDE, as can be seen in **Figure 5A**, are a conservative estimate of
406 nD_{lung} , with the vast majority of the data points falling within 30% of SSDE ($C_p = 92.5\%$). Additionally,
407 as can also be seen in **Figure 5A**, nD_{lung} values and regression fits tend to track closer to SSDE with

408 increasing D_w , most probably due to the response of the AEC system of maxing out tube current output
 409 for larger-sized patients. **Figure 7** below shows the TCM profile of a non-bariatric and a bariatric patient
 410 administered a routine chest exam. In **Figure 7B**, this TCM profile has very little longitudinal modulation
 411 due to the attenuation characteristics of the patient. Although the number of bariatric patients in this study
 412 was limited, this trend may nevertheless suggest different regimes within the normalized dose curves in
 413 relation to tube output potential of a scanner and patient size.

414



415

416 **Figure 7:** Examples of TCM profile from a routine chest exam of a **A)** typical, non-bariatric patient and
 417 **B)** bariatric patient. In **B)**, longitudinal modulation is minimal due to patient size and tube current
 418 limitation.

419

420 This study observed that the T_U for the difference between nD_{breast} and SSDE needed to cover
 421 95% of the population with 95% confidence was observed to be 68.3%. These observations can be seen
 422 more clearly in **Figure 5B** for nD_{breast} values, as well as the corresponding regression fits between
 423 nD_{breast} and D_w , were systematically below SSDE with only a few exceptions (nD_{breast} : $\overline{\Delta D_{SSDE, breast}} =$
 424 31.8%, $\Delta S_{SSDE, breast} = 18.7\%$). As was seen in the lung, the normalized breast dose from TCM is
 425 systematically smaller than SSDE. Thus, this study suggests that SSDE may be a conservative estimate
 426 for nD_{breast} for most of the population. A tolerance wider than the 20% difference between patient dose
 427 and SSDE specified in AAPM Report 204 would be needed to encompass 95% with 95% confidence of
 428 nD_{breast} .

429 For abdomen/pelvis exams, this study found that that the T_U for the difference between nD_{liver} ,
430 nD_{spleen} , and nD_{kidney} and SSDE needed to cover 95% of the population with 95% confidence was 30.7%,
431 33.2%, and 33.0%, respectively. These results indicate that a tolerance wider than a 20% difference
432 between SSDE and $CTDI_{vol,32}$ -normalized organ dose would be needed to capture 95% of nD_{liver} , nD_{spleen} ,
433 and nD_{kidney} cases with 95% confidence. These results are illustrated in the **Figure 6** for nD_{liver} , nD_{spleen} ,
434 and nD_{kidney} , respectively, wherein, for all three organs, the vast majority of the nD_{liver} , nD_{spleen} , and
435 nD_{kidney} cases are within 30% of SSDE ($C_p = 97.2\%$, $C_p = 92.5\%$, and $C_p = 93.5\%$, respectively).
436 Additionally, as can be seen in **Table 9**, all three of these organs had fairly similar deviations from SSDE
437 as indicated by the proximity of their $\overline{\Delta D_{SSDE,organ}}$ and $\Delta S_{SSDE,organ}$ values to one another. Given this, an
438 equivalent T_U for these three organs of the abdomen/pelvis is a reasonable result.

439 A general trend was observed that normalized doses from TCM protocols were lower than SSDE.
440 This observation is intuitive given that TCM reduces normalized dose relative to FTC [29]. The data
441 suggests that another model of normalized dose that takes into consideration the effects of TCM may be
442 needed. A potential candidate for such a dose model that considers TCM is the generalized linear model
443 (GLM) developed by Bostani et al. [30]. The GLM is a statistical dose model that allows for the inclusion
444 of categorical variables for different radiosensitive organs and scanners and was constructed with TCM
445 MC simulations [30]. Given the widespread use of TCM, it is possible that normalized dose coefficients
446 derived from GLM may be more appropriate in the current context of clinical practice. This, though,
447 would require further investigation.

448 This study had a few advantages. This study capitalized on the strengths of the direct MC
449 simulation approach to evaluate SSDE in light of organ dose estimates that are reflective of actual patient
450 anatomy and actual, clinical TCM schemes. The evaluation of SSDE was performed on a per-organ basis
451 using those MC-derived organ dose estimates across a range of patient sizes and across several routine
452 protocols. Even given these advantages, however, this study nevertheless had a few limitations. For head
453 exams, though the expectation is that brain parenchyma dose from FTC will not significantly deviate from
454 SSDE, the sample sizes were nevertheless small because organ dose data was based on previous work.

455 Future work would involve using a large sample size to evaluate SSDE for the doses for this protocol. For
456 those routine examinations employing TCM, which was the majority of the protocols investigated herein,
457 only one AEC algorithm from one manufacturer, Siemens, was considered due to the lack of accessibility
458 of complete TCM information from other scanner manufacturers. Future work would involve performing
459 the direct simulation method with TCM information from other manufacturers and scanners. Additionally,
460 though this study attempted to evaluate SSDE across a range of patient sizes, this study only contained a
461 limited number of bariatric patients. Future work in this avenue would involve the incorporation of more
462 bariatric patients in the evaluation of SSDE.

463

464 **5. CONCLUSION**

465 This study evaluated SSDE as an estimate of organ dose in light of organ dose estimates from
466 direct MC simulation methods, using the 20% threshold mentioned in AAPM Report 204 as the point of
467 departure for the evaluation. In the case of routine exams, with the exception of brain parenchyma doses
468 routine FTC head exams, the null hypothesis of this study was rejected in that T_U was found to be greater
469 than 20% for the organ doses investigated from body routine exams. Results indicate that a 20% threshold
470 difference is most likely sufficient for 95% coverage of brain parenchyma dose cases from routine FTC
471 head exams. For body exams using TCM, a threshold difference of ~30-36% would be wide enough to
472 cover the majority (95%) of the organs investigated in this study, excluding the breasts, where SSDE
473 serves as a conservative estimate.

474

475 **REFERENCES**

- 476 [1] F. A. Mettler *et al.*, “Radiologic and Nuclear Medicine Studies in the United States and
477 Worldwide: Frequency, Radiation Dose, and Comparison with Other Radiation Sources—1950–
478 2007,” *Radiology*, vol. 253, no. 2, pp. 520–531, 2009.
- 479 [2] R. Smith-Bindman *et al.*, “Radiation Doses in Consecutive CT Examinations from Five University
480 of California Medical Centers,” *Radiology*, vol. 277, no. 1, pp. 134–141, May 2015.

- 481 [3] C. H. McCollough, S. Leng, L. Yu, D. D. Cody, J. M. Boone, and M. F. McNitt-Gray, "CT dose
482 index and patient dose: they are not the same thing.," *Radiology*, vol. 259, no. 2, pp. 311–316,
483 2011.
- 484 [4] Computerized Imaging Reference Systems Inc., "ATOM Dosimetry Verification Phantoms."
485 [Online]. Available: [http://www.cirsinc.com/products/radiation-therapy/atom-dosimetry-
486 verification-phantoms/](http://www.cirsinc.com/products/radiation-therapy/atom-dosimetry-verification-phantoms/). [Accessed: 30-Apr-2019].
- 487 [5] D. Zhang *et al.*, "In vitro dose measurements in a human cadaver with abdomen/pelvis CT scans,"
488 *Med. Phys.*, vol. 41, no. 9, pp. 1–9, 2014.
- 489 [6] J. W. Mueller *et al.*, "In vivo CT dosimetry during CT colonography," *Am. J. Roentgenol.*, vol.
490 202, no. 4, pp. 703–710, 2014.
- 491 [7] D. Zhang *et al.*, "Variability of surface and center position radiation dose in MDCT: Monte Carlo
492 simulations using CTDI and anthropomorphic phantoms.," *Med. Phys.*, vol. 36, no. 3, pp. 1025–
493 38, 2009.
- 494 [8] W. P. Segars, M. Mahesh, T. J. Beck, E. C. Frey, and B. M. W. Tsui, "Realistic CT simulation
495 using the 4D XCAT phantom.," *Med. Phys.*, vol. 35, no. 8, pp. 3800–3808, 2008.
- 496 [9] AAPM Task Group 195, "Monte Carlo Reference Data Sets for Imaging Research," College Park,
497 MD, 2015.
- 498 [10] A. J. Hardy, M. Bostani, E. Angel, C. Cagnon, I. Sechopoulos, and M. F. McNitt-Gray,
499 "Reference dataset for benchmarking fetal doses derived from Monte Carlo simulations of CT
500 exams," *Med. Phys.*, vol. n/a, no. n/a, Oct. 2020.
- 501 [11] AAPM Task Group 204, "Size-Specific Dose Estimates (SSDE) in Pediatric and Adult Body CT
502 Examinations," College Park, MD, Jan. 2011.
- 503 [12] AAPM Task Group 293, "Size-Specific Dose Estimate (SSDE) for Head CT: The Report of
504 AAPM," College Park, MD, 2019.
- 505 [13] B. M. Moore, S. L. Brady, A. E. Mirro, and R. A. Kaufman, "Size-specific dose estimate (SSDE)
506 provides a simple method to calculate organ dose for pediatric CT examinations," *Med. Phys.*, vol.

507 41, no. 7, pp. 1–10, 2014.

508 [14] T. M. Griglock *et al.*, “Determining Organ Doses from CT with Direct Measurements in
509 Postmortem Subjects: Part 1—Methodology and Validation,” *Radiology*, vol. 277, no. 2, pp. 463–
510 470, 2015.

511 [15] AAPM Task Group 220, “Use of Water Equivalent Diameter for Calculating Patient Size and
512 Size-Specific Dose Estimates (SSDE) in CT,” College Park, MD, 2014.

513 [16] C. Lee, K. P. Kim, D. J. Long, and W. E. Bolch, “Organ doses for reference pediatric and
514 adolescent patients undergoing computed tomography estimated by Monte Carlo simulation,”
515 *Med. Phys.*, vol. 39, no. 4, pp. 2129–2146, 2012.

516 [17] X. Li *et al.*, “Patient-specific radiation dose and cancer risk estimation in CT: Part II. Application
517 to patients,” *Med. Phys.*, vol. 38, no. 1, pp. 408–419, 2011.

518 [18] A. J. Hardy *et al.*, “Estimating a size-specific dose for helical head CT examinations using Monte
519 Carlo simulation methods,” *Med. Phys.*, vol. 46, no. 2, pp. 902–912, Feb. 2019.

520 [19] N. Petoussi-Henss, M. Zankl, U. Fill, D. Regulla, and M. Zanki, “The GSF family of voxel
521 phantoms,” *Phys. Med. Biol.*, vol. 47, no. 1, pp. 89–106, 2002.

522 [20] International Commission on Radiological Protection, “Adult reference computational phantoms,”
523 *ICRP Publ. 110. Ann. ICRP 39*, vol. (2), 2009.





524 [21] M. Zankl, K. F. Eckerman, and W. E. Bolch, “Voxel-based models representing the male and
525 female ICRP reference adult - The skeleton,” *Radiat. Prot. Dosimetry*, vol. 127, no. 1–4, pp. 174–
526 186, 2007.

527 [22] J. J. Demarco, T. D. Solberg, and J. B. Smathers, “A CT-based Monte Carlo simulation tool for
528 dosimetry planning and analysis,” *Med. Phys.*, vol. 25, pp. 1–11, 1998.

529 [23] M. Bostani *et al.*, “Accuracy of Monte Carlo simulations compared to in-vivo MDCT dosimetry.,”
530 *Med. Phys.*, vol. 42, no. 2, p. 1080, 2015.



531 [24] E. Angel *et al.*, “Monte Carlo simulations to assess the effects of tube current modulation on breast
532 dose for multidetector CT,” *Phys Med Biol*, vol. 54, no. 3, pp. 497–512, 2010.









- 533 [25] C. H. McCollough *et al.*, “Use of water equivalent diameter for calculating patient size and size-
534 specific dose estimates (SSDE) in CT,” 2014.
- 535 [26] A. C. Turner *et al.*, “A method to generate equivalent energy spectra and filtration models based
536 on measurement for multidetector CT Monte Carlo dosimetry simulations,” *Med. Phys.*, vol. 36,
537 no. 6, 2009.
- 538 [27] J. J. DeMarco *et al.*, “A Monte Carlo based method to estimate radiation dose from multidetector
539 CT (MDCT): cylindrical and anthropomorphic phantoms.,” *Phys. Med. Biol.*, vol. 50, no. 17, pp.
540 3989–4004, 2005.
- 541 [28] National Institute of Standards and Technology, “Engineering Statistics Handbook: Tolerance
542 intervals for a normal distribution.” [Online]. Available:
543 <https://www.itl.nist.gov/div898/handbook/prc/section2/prc263.htm#cases>. [Accessed: 28-Aug-
544 2019].
- 545 [29] E. Angel *et al.*, “Dose to radiosensitive organs during routine chest CT: Effects of tube current
546 modulation,” *Am. J. Roentgenol.*, vol. 193, no. 5, pp. 1340–1345, 2009.
- 547 [30] M. Bostani *et al.*, “Estimating organ doses from tube current modulated CT examinations using a
548 generalized linear model,” *Med. Phys.*, vol. 44, no. 4, pp. 1500–1513, 2017.
- 549
550




Legend for segmentation colors:

- Orange: Breast/muscle
- Red: Bone
- Blue: Air
- Green: Adipose
- Cyan: Lung/cloth/table



- | | | | |
|--|--|---|---|
|  Liver |  Muscle |  Bone |  Cloth |
|  Kidney |  Spleen |  Adipose |  Air |



Brain Dose - FTC Routine Head Exam

